Premium
Effect of High‐ versus Intermediate‐Purity Blood Coagulation Factor Concentrates on HIV‐1 Replication
Author(s) -
Schögl Daniela,
Zimmermann Klaus,
Turecek Peter L.,
Schwarz Hans Peter,
Eibl Martha M.,
Mannhalter Josef W.
Publication year - 1996
Publication title -
vox sanguinis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.68
H-Index - 83
eISSN - 1423-0410
pISSN - 0042-9007
DOI - 10.1111/j.1423-0410.1996.tb01325.x
Subject(s) - coagulation , replication (statistics) , virology , human immunodeficiency virus (hiv) , viral replication , immunology , in vivo , viral load , whole blood , coagulation system , incubation period , biology , medicine , incubation , virus , genetics , biochemistry
Controversy exists as to whether treatment of HIV‐1‐seropositive hemophiliacs with blood coagulation products of high purity might help prevent the decline of CD4‐positive lymphocytes and thus delay progression toward AIDS. As viral load has recently been shown to be associated with disease progression in HIV‐1 infection, we tested for a possible direct interference of high‐ or intermediate‐purity blood coagulation products with replication of HIV‐1. The data obtained revealed comparable replication of HIV‐1 in the presence and absence of all blood coagulation products tested (assessed by PCR‐based quantitation of proviral HIV‐1 DNA in infected cells after a 10‐day incubation period). These data suggest that coagulation factor concentrates per se will also have no direct effect on HIV‐1 replication in vivo.